These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
688 related articles for article (PubMed ID: 32220970)
1. Long Noncoding RNA MALAT1 Contributes to Sorafenib Resistance by Targeting miR-140-5p/Aurora-A Signaling in Hepatocellular Carcinoma. Fan L; Huang X; Chen J; Zhang K; Gu YH; Sun J; Cui SY Mol Cancer Ther; 2020 May; 19(5):1197-1209. PubMed ID: 32220970 [TBL] [Abstract][Full Text] [Related]
2. lncRNA-POIR promotes epithelial-mesenchymal transition and suppresses sorafenib sensitivity simultaneously in hepatocellular carcinoma by sponging miR-182-5p. Chen BW; Zhou Y; Wei T; Wen L; Zhang YB; Shen SC; Zhang J; Ma T; Chen W; Ni L; Wang Y; Bai XL; Liang TB J Cell Biochem; 2021 Jan; 122(1):130-142. PubMed ID: 32951268 [TBL] [Abstract][Full Text] [Related]
3. Long noncoding RNA LEF1-AS1 acts as a microRNA-10a-5p regulator to enhance MSI1 expression and promote chemoresistance in hepatocellular carcinoma cells through activating AKT signaling pathway. Gao J; Dai C; Yu X; Yin XB; Zhou F J Cell Biochem; 2021 Jan; 122(1):86-99. PubMed ID: 32786108 [TBL] [Abstract][Full Text] [Related]
4. SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23b-3p via sponging EGR1 in hepatocellular carcinoma. Jing Z; Ye X; Ma X; Hu X; Yang W; Shi J; Chen G; Gong L Cancer Med; 2020 Jun; 9(12):4324-4338. PubMed ID: 32324343 [TBL] [Abstract][Full Text] [Related]
5. LncRNA TTN-AS1 intensifies sorafenib resistance in hepatocellular carcinoma by sponging miR-16-5p and upregulation of cyclin E1. Zhou Y; Huang Y; Dai T; Hua Z; Xu J; Lin Y; Han L; Yue X; Ho L; Lu J; Ai X Biomed Pharmacother; 2021 Jan; 133():111030. PubMed ID: 33378944 [TBL] [Abstract][Full Text] [Related]
6. Long noncoding RNA UPK1A-AS1 indicates poor prognosis of hepatocellular carcinoma and promotes cell proliferation through interaction with EZH2. Zhang DY; Sun QC; Zou XJ; Song Y; Li WW; Guo ZQ; Liu SS; Liu L; Wu DH J Exp Clin Cancer Res; 2020 Oct; 39(1):229. PubMed ID: 33121524 [TBL] [Abstract][Full Text] [Related]
7. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells. Li W; Dong X; He C; Tan G; Li Z; Zhai B; Feng J; Jiang X; Liu C; Jiang H; Sun X J Exp Clin Cancer Res; 2019 May; 38(1):183. PubMed ID: 31053148 [TBL] [Abstract][Full Text] [Related]
8. LncRNA MALAT1 mediates doxorubicin resistance of hepatocellular carcinoma by regulating miR-3129-5p/Nova1 axis. Cao Y; Zhang F; Wang H; Bi C; Cui J; Liu F; Pan H Mol Cell Biochem; 2021 Jan; 476(1):279-292. PubMed ID: 32965597 [TBL] [Abstract][Full Text] [Related]
9. N Xu J; Wan Z; Tang M; Lin Z; Jiang S; Ji L; Gorshkov K; Mao Q; Xia S; Cen D; Zheng J; Liang X; Cai X Mol Cancer; 2020 Nov; 19(1):163. PubMed ID: 33222692 [TBL] [Abstract][Full Text] [Related]
10. Long Non-Coding MALAT1 Functions as a Competing Endogenous RNA to Regulate Vimentin Expression by Sponging miR-30a-5p in Hepatocellular Carcinoma. Pan Y; Tong S; Cui R; Fan J; Liu C; Lin Y; Tang J; Xie H; Lin P; Zheng T; Yu X Cell Physiol Biochem; 2018; 50(1):108-120. PubMed ID: 30278452 [TBL] [Abstract][Full Text] [Related]
11. lncRNA A1BG-AS1 suppresses proliferation and invasion of hepatocellular carcinoma cells by targeting miR-216a-5p. Bai J; Yao B; Wang L; Sun L; Chen T; Liu R; Yin G; Xu Q; Yang W J Cell Biochem; 2019 Jun; 120(6):10310-10322. PubMed ID: 30556161 [TBL] [Abstract][Full Text] [Related]
12. DEAD-Box Helicase 17 circRNA (circDDX17) Reduces Sorafenib Resistance and Tumorigenesis in Hepatocellular Carcinoma. Zhang X; Wang W; Mo S; Sun X Dig Dis Sci; 2024 Jun; 69(6):2096-2108. PubMed ID: 38653946 [TBL] [Abstract][Full Text] [Related]
13. LncRNA FOXD2-AS1 as a competitive endogenous RNA against miR-150-5p reverses resistance to sorafenib in hepatocellular carcinoma. Sui C; Dong Z; Yang C; Zhang M; Dai B; Geng L; Lu J; Yang J; Xu M J Cell Mol Med; 2019 Sep; 23(9):6024-6033. PubMed ID: 31210410 [TBL] [Abstract][Full Text] [Related]
14. TRERNA1 upregulation mediated by HBx promotes sorafenib resistance and cell proliferation in HCC via targeting NRAS by sponging miR-22-3p. Song W; Zheng C; Liu M; Xu Y; Qian Y; Zhang Z; Su H; Li X; Wu H; Gong P; Li Y; Fan H Mol Ther; 2021 Aug; 29(8):2601-2616. PubMed ID: 33839325 [TBL] [Abstract][Full Text] [Related]
15. miR-124-3p availability is antagonized by LncRNA-MALAT1 for Slug-induced tumor metastasis in hepatocellular carcinoma. Cui RJ; Fan JL; Lin YC; Pan YJ; Liu C; Wan JH; Wang W; Jiang ZY; Zheng XL; Tang JB; Yu XG Cancer Med; 2019 Oct; 8(14):6358-6369. PubMed ID: 31466138 [TBL] [Abstract][Full Text] [Related]
16. SNHG16 as the miRNA let-7b-5p sponge facilitates the G2/M and epithelial-mesenchymal transition by regulating CDC25B and HMGA2 expression in hepatocellular carcinoma. Li S; Peng F; Ning Y; Jiang P; Peng J; Ding X; Zhang J; Jiang T; Xiang S J Cell Biochem; 2020 Mar; 121(3):2543-2558. PubMed ID: 31696971 [TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA SBF2-AS1 promotes hepatocellular carcinoma progression through regulation of miR-140-5p-TGFBR1 pathway. Li Y; Liu G; Li X; Dong H; Xiao W; Lu S Biochem Biophys Res Commun; 2018 Sep; 503(4):2826-2832. PubMed ID: 30115383 [TBL] [Abstract][Full Text] [Related]
18. Enhancer of zeste 2 polycomb repressive complex 2 subunit promotes sorafenib resistance of hepatocellular carcinoma though insulin-like growth factor 1 receptor. Hu J; Zhang J; Sun F; Qi M; Su P; Liu H; Gao L; Jiao M; Wu Z; Xiang L; Han B Anticancer Drugs; 2019 Aug; 30(7):e0746. PubMed ID: 31305292 [TBL] [Abstract][Full Text] [Related]
19. An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells. Tang S; Tan G; Jiang X; Han P; Zhai B; Dong X; Qiao H; Jiang H; Sun X Oncotarget; 2016 Nov; 7(45):73257-73269. PubMed ID: 27689326 [TBL] [Abstract][Full Text] [Related]
20. A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis. Wang Y; Yang L; Chen T; Liu X; Guo Y; Zhu Q; Tong X; Yang W; Xu Q; Huang D; Tu K Mol Cancer; 2019 Feb; 18(1):28. PubMed ID: 30782188 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]